Preparing for the renaissance: treating breast cancer during the COVID-19 pandemic and planning for a safe re-emergence to routine surgical care within a universal health care system.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed, 10 citations in OpenAlex.

1. Breast Cancer Surgery Wait Times and COVID-19: A Canadian Population-Based Analysis.Annals of surgical oncology · 2026
   Article
2. ASO Author Reflections: Patterns of Breast Cancer Management and Surgical Wait Times During the COVID-19 Pandemic.Annals of surgical oncology · 2026
   Article
3. The impact of the COVID-19 pandemic on breast cancer screening, treatment, and overall survival.Breast cancer research and treatment · 2026
   Article
4. Impact of the COVID-19 pandemic on breast cancer surgeries in a Canadian population.Breast cancer research and treatment · 2025
   Article
5. Breast Cancer Management in the Era of Covid-19; Key Issues, Contemporary Strategies, and Future Implications.Breast cancer (Dove Medical Press) · 2023
   Review
6. When to operate after SARS-CoV-2 infection? A review on the recent consensus recommendation of the DGC/BDC and the DGAI/BDA.Langenbeck's archives of surgery · 2022
   Review
7. Analysis of Facilitators and Barriers to the Delivery of Routine Care during the COVID-19 Global Pandemic: A Systematic Review.Healthcare (Basel, Switzerland) · 2021
   Review
8. Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global Pandemic.Current oncology (Toronto, Ont.) · 2021
   Review
9. Triple-Negative Breast Cancer and the COVID-19 Pandemic: Clinical Management Perspectives and Potential Consequences of Infection.Cancers · 2021
   Review
10. Impact of the COVID-19 pandemic on cancer diagnosis, treatment and research in African health systems: a review of current evidence and contextual perspectives.Ecancermedicalscience · 2021
    Review

Corrections and comments

• Comment on
  Preoperative Delays in the Treatment of DCIS and the Associated Incidence of Invasive Breast Cancer.2020

Authors and funding

3 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as